The authors reply

Podobne zapisy

• Sacubitril/valsartan in peritoneal dialysis—lessons from a pharmacokinetic study
  od: Judge, PK, i wsp.
  Wydane: (2023)
• Allocated but not treated: the silent 16% – Authors' reply
  od: Horby, P, i wsp.
  Wydane: (2022)
• Authors' reply
  od: Herrington, W, i wsp.
  Wydane: (2018)
• Impact of primary kidney disease on the effects of empagliflozin in patients with CKD
  od: Judge, PK, i wsp.
  Wydane: (2023)
• The prevention and management of chronic kidney disease among patients with metabolic syndrome
  od: Zhu, D, i wsp.
  Wydane: (2025)